References
- Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Stacker SA, et al 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548–553
- Aruffo A, Seed B. 1987. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 84:8573–8577
- Burgess AW. 1988. Growth factors: the beginnings. Growth Factors 1:1–6
- Burgess AW. 2008. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 26:263–274
- Dancey J, Sausville EA. 2003. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296–313
- Folkman J. 1972. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409–416
- Grobstein C. 1977. The recombinant-DNA debate. Sci Am 237:22–33
- Gu H, Zou YR, Rajewsky K. 1993. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73:1155–1164
- Hanks SK, Quinn AM, Hunter T. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42–52
- Hunter T. 1987. A thousand and one protein kinases. Cell 50:823–829
- Hynes NE, Lane HA. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354
- Imai K, Takaoka A. 2006. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6:714–727
- Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Alitalo K, et al 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290–298
- Kitano H. 2002. Systems biology: a brief overview. Science 295:1662–1664
- Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (London) 256:495–497
- Lieschke GJ, Burgess AW. 1992a. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 327:99–106
- Lieschke GJ, Burgess AW. 1992b. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 327:28–35
- Maxam AM, Gilbert W. 1977. A new method for sequencing DNA. Proc Natl Acad Sci USA 74:560–564
- McDonald NQ, Hendrickson WA. 1993. A structural superfamily of growth factors containing a cystine knot motif. Cell 73:421–424
- Morstyn G, Burgess AW. 1988. Hemopoietic growth factors: a review. Cancer Res 48:5624–5637
- Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Eriksson U, et al 1996. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576–2581
- Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. 1996. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA 93:11675–11680
- Pawson T. 1995. Protein modules and signalling networks. Nature 373:573–580
- Pawson T, Nash P. 2003. Assembly of cell regulatory systems through protein interaction domains. Science 300:445–452
- Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Lapidot T, et al 2002. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687–694
- Robinson DR, Wu YM, Lin SF. 2000. The protein tyrosine kinase family of the human genome. Oncogene 19:5548–5557
- Sadowski I, Stone JC, Pawson T. 1986. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol 6:4396–4408
- Sander JD, Joung JK. 2014. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32:347–355
- Sanger F, Coulson AR. 1975. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 94:441–448
- Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74:5463
- Scott AM, Wolchok JD, Old LJ. 2012. Antibody therapy of cancer. Nat Rev Cancer 12:278–287
- Sefton BM, Hunter T, Beemon K. 1980. Relationship of polypeptide products of the transforming gene of Rous sarcoma virus and the homologous gene of vertebrates. Proc Natl Acad Sci USA 77:2059–2063
- Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985
- Tammela T, Enholm B, Alitalo K, Paavonen K. 2005. The biology of vascular endothelial growth factors. Cardiovasc Res 65:550–563
- Thomas KR, Capecchi MR. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51:503–512
- Ullrich A, Schlessinger J. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212
- Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Zhu X, et al 2001. The sequence of the human genome. Science 291:1304–1351
- Wilks AF. 1989. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 86:1603–1607
- Williams AF, Barclay AN. 1988. The immunoglobulin superfamily-domains for cell surface recognition. Ann Rev Immunol 6:381–405
- Yarden Y, Schlessinger J. 1987. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26:1443–1451